Series date: 
01/01/2025 - 7:30am to 12/31/2025 - 8:30am
COURSE DIRECTOR
David Dingli, M.D., and Hassan Alkhateeb, M.D.

DESCRIPTION
This is a course intended for Mayo personnel only. It is a multidisciplinary Adult and Pediatric forum designed to enhance the practice and ensure excellence in all aspects of BMT. We discuss the onboarding of novel stem cell-based technologies such as gene therapy. In addition, we also discuss controversial cases as part of a patient selection process, presenting the data and literature in support and against transplantation for a specific circumstance. (Providers, APP, Nursing, Human cell Therapy, Transfusion medicine, Nutrition/ Dietetics, Pharmacy, Social work) 

Live-Streamed; Weekly on Wednesday from 7:30-8:30 a.m.

TARGET AUDIENCE
Allied Health Professionals, Healthcare Executives, Nurses, Nurse Practitioners, Pharmacists, Physicians, Physician Assistants, Psychologists, Registered Dietitians, Resident Fellows, Scientist Researcher, PhDs, Social Workers, and Students.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
  • Discuss new stem cell directed therapies that will soon be offered at Mayo Clinic.
  • List innovation/change in BMT that is relevant to the daily practice.

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


CREDIT STATEMENT(S)
AMA

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE SUMMARY
As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities.  All who are in a position to control the content are required to disclose all financial relationships with any ineligible company.   Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationship(s) with ineligible companies: 

David Dingli, M.D. - Consultant - 21GRAMS; Advarra; Alexion Pharmaceuticals, Inc.; Apellis Pharmaceuticals; Argenx US Inc; AstraZeneca Pharmaceuticals LP; Curio Science LLC; DAVA Oncology, LP; Engage Health Media; Immunome, Inc.; Janssen Biotech, Inc., Janssen Scientific Affairs, LLC; Legend Biotech USA Inc; Merck Sharp & Dohme Corp.; Novartis; Novartis Pharmaceuticals Corporation; Ossium Health, Inc.; ReachMD; Regeneron Pharmaceuticals, Inc.; Remedy Health Media; UCB Pharma GmbH; Intellectual Property - Physician Software Systems (PhySoft)

All relevant financial relationships have been mitigated. 
 
No relevant financial relationship(s) with ineligible companies:
Hassan Alkhateeb, M.D.
Mikayla Baumgartner (Coordinator)
Kassy McCarty (Coordinator)

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:
None

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
 
ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.
 
TRANSCRIPT
Any credit or attendance awarded will appear on your Transcript.

QUESTIONS?
Contact Mikayla Baumgartner or Kassy McCarty
Where did the idea for the course originate?: 
Minnesota

Sessions

Session Date
Bone Marrow Transplant Weekly Meeting 2025 Inpatient Outpatient Services aGVHD SOP GATA2 Deficiency syndrome Flesh and Blood 10/15/2025 - 7:30am to 8:30am
Bone Marrow Transplant Weekly Meeting 2025 Inpatient Outpatient Services Extended Stay BMT Inpatients 10 22 25 10/22/2025 - 7:30am to 8:30am
Bone Marrow Transplant Weekly Meeting 2025 Inpatient Outpatient Services Early mortality case review Patient selection conference 10/29/2025 - 7:30am to 8:30am
Bone Marrow Transplant Weekly Meeting 2025 Inpatient Outpatient Services Conditioning regimen prior auth process 11 5 25 11/05/2025 - 7:30am to 8:30am
Bone Marrow Transplant Weekly Meeting 2025 Inpatient Outpatient Services Journal Club Matched Unrelated vs Haploidentical Donor Transplantation with Post Transplant Cyclophosphamide Dipenkumar Modi et al Blood Advances 11/12/2025 - 7:30am to 8:30am
Bone Marrow Transplant Weekly Meeting 2025 Inpatient Outpatient Services 11 19 25 11/19/2025 - 7:30am to 8:30am
Bone Marrow Transplant Weekly Meeting 2025 Inpatient Outpatient Services Abstract Comparative analysis of allogeneic hematopoietic stem cell transplantation vs hypomethylating agents in VEXAS syndrome Patient selection conference 11/26/2025 - 7:30am to 8:30am
Bone Marrow Transplant Weekly Meeting 2025 Inpatient Outpatient Services Patient Selection Conference Extended Stay BMT Inpatients REF 2055 order placement reminder 12/03/2025 - 7:30am to 8:30am
Bone Marrow Transplant Weekly Meeting 2025 Inpatient Outpatient Services Journal Club Preventing Allogeneic Stem Cell Transplant Related Cardiovascular Dysfunction ALLO Active Trial Circulation Epic Tips and Tricks 12/10/2025 - 7:30am to 8:30am

Pages